Form 4: Syra Health Corp Director Acquires Stock Options

A Syra Health Corp director, Vijayapal Reddy, acquired 12,136 stock options on January 7, 2025, under the company's 2022 Omnibus Equity Incentive Plan.

Summary

• Vijayapal Reddy, a director at Syra Health Corp, has acquired 12,136 stock options.
• The options were granted on January 7, 2025, with an exercise price of $0.7386 per share.
• These options were issued under the company's 2022 Omnibus Equity Incentive Plan.
• 25% of the options vested immediately upon grant, and the remaining options will vest in 12 equal monthly installments.
• The options expire on January 7, 2035.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is neither particularly positive nor negative. It is a neutral event from an investment perspective.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.
• The vesting schedule of the options incentivizes the director to remain engaged with the company over the next year.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 25% immediately and the remainder over 12 months is a fairly standard approach to align director interests with company performance.
• The exercise price of $0.7386 is specific to Syra Health Corp and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns director interests with company performance.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, Syra Health Corp, beneficial ownership